Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

about

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

Item

http://www.wikidata.org/entity/Q55285332

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@en

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@nl

type

Item

label

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@en

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@nl

prefLabel

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@en

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@nl

P1476

Evaluation of Treatment Effect ...... rm Phase II Trial in Oncology.

@en

P2093

Matthieu Texier

http://www.w3.org/2001/XMLSchema#string

Michel Ducreux

http://www.w3.org/2001/XMLSchema#string

Olivier Bouché

http://www.w3.org/2001/XMLSchema#string

P2860

A power analysis of tests for paired lifetime data.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

P304

1672176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/1672176

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Federico Rotolo

Stefan Michiels

Jean-Pierre Pignon

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29568321

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

5820554

http://www.w3.org/2001/XMLSchema#string